Investigation of the utility of lymph node fine needle aspiration cytology for the staging of malignant solid tumors in dogs by Fournier, Quentin et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investigation of the utility of lymph node fine needle aspiration
cytology for the staging of malignant solid tumors in dogs
Citation for published version:
Fournier, Q, Cazzini, P, Bavcar, S, Pecceu, E, Ballber, C & Elders, R 2018, 'Investigation of the utility of
lymph node fine needle aspiration cytology for the staging of malignant solid tumors in dogs' Veterinary
Clinical Pathology.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Veterinary Clinical Pathology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 20. Jul. 2018
  
Investigation of the utility of lymph node fine needle aspiration cytology for the staging 1 
of malignant solid tumors in dogs 2 
Quentin Fournier1, Paola Cazzini2, Spela Bavcar1, Evi Pecceu1, Clara Ballber1,3, and Richard 3 
Elders1,4. 4 
Departments of 1Small Animal Teaching Hospital and 2Easter Bush Pathology, The Royal 5 
(Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, Easter 6 
Bush, Edinburgh, UK 7 
3Dr. Ballber’s current address is: Wood Street Veterinary Hospital, London, UK 8 
4Dr Elders’ current address is: IDEXX Laboratories, Wetherby, UK 9 
 
Corresponding author: 10 
Quentin Fournier 11 
Small Animal Hospital 12 
Royal (Dick) School of Veterinary Studies 13 
University of Edinburgh  14 
Easter Bush Campus 15 
EH25 9RG 16 
United-Kingdom 17 
qfournie@exseed.ed.ac.uk 18 
 
  
Keywords: Canine, cytology, lymphatic metastasis, sensitivity 19 
Running Head: Lymph node cytology in cancer staging 20 
 
Data presented in part at the joint European Society of Veterinary Oncology and European 21 
Society of Veterinary Clinical Pathology Annual Congress, Nantes, France, 2016.  22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Abstract  23 
 
Background: Fine needle aspiration cytology (FNAC) of lymph nodes (LNs) is routinely 24 
used for staging canine malignant solid tumors, but studies evaluating its efficacy are limited.  25 
Objectives: The primary objectives of this study were to evaluate the sensitivity/specificity 26 
of FNAC and the significance of non-diagnostic FNAC when staging canine malignant solid 27 
tumors. A secondary objective was to determine the frequency of multiple nodal metastases. 28 
Methods: Histopathological and FNAC assessments of LNs (n = 259) draining malignant 29 
solid tumors were included. The sensitivity/specificity of FNAC was determined for 194 LNs 30 
with diagnostic FNAC, using histopathology as the gold standard. The proportion of non-31 
diagnostic FNAC and associated histopathological prevalence of metastasis were determined. 32 
Among the tumors with multiple LNs assessed (88/189), the prevalence of multiple nodal 33 
metastases was determined. 34 
Results: The sensitivity of FNAC was 67% for sarcomas, 100% for carcinomas, 63% for 35 
melanomas, 75% for mast cell tumors, and 100% for other round cell tumors. The specificity 36 
varied between 83% and 96%. Non-diagnostic FNAC was reported in 25% of LNs sampled, 37 
most of which were non-enlarged and/or difficult to access, and 20% of which were 38 
metastatic on histopathology. When several LNs were assessed, the prevalence of multiple 39 
nodal metastases was 24%. 40 
Conclusions: Histopathologic LN evaluation cannot be robustly substituted with FNAC 41 
when staging selected canine solid tumors. When a diagnostic FNAC is elusive, as the 42 
prevalence of metastasis remains non-negligible in these cases, histopathological assessment 43 
is ideal. Finally, staging should not always be limited to the assessment of one single LN.  44 
 
  
Introduction 45 
 Assessment of the loco-regional lymph nodes (LNs) is an integral part of the TNM 46 
clinical staging system for canine solid tumors, from the original version of the World Health 47 
Organization (WHO) staging scheme created in 1980,1 to the more recently published staging 48 
schemes.2-4 Loco-regional LN metastatic status has been correlated with prognosis in several 49 
tumor types, and represents a key element for the clinician to devise an appropriate, bespoke 50 
treatment plan for each individual tumor-bearing canine patient.5, 6 Although histopathologic 51 
examination was the method originally recommended in the WHO staging system to assess 52 
regional LN status,1 assessment of the regional LNs in veterinary medicine is often performed 53 
using fine-needle aspiration cytology (FNAC). As it is a non-invasive, cost-effective, and 54 
rapid technique, FNAC is very appealing. In a large retrospective study, tumor staging was 55 
the second most common reason for sampling LNs, leading to the submission of 9.3% of LN 56 
FNAC.7 In a prospective study including 37 dogs diagnosed with a variety of tumors (16 57 
carcinomas, 18 sarcomas, 7 mast cell tumors, 2 melanomas and 1 histiocytic sarcoma), the 58 
sensitivity and specificity of FNAC for assessing regional LNs were 100% and 96% 59 
respectively, with histopathology used as the gold standard.8 In another prospective study 60 
including 28 dogs with oral or maxillofacial neoplasms (8 squamous cell carcinomas, 5 61 
fibrosarcomas, 5 melanomas and 10 other tumors), the accuracy of FNAC for LN staging was 62 
90.5% when compared with histopathology.9 Similarly, in a recent large retrospective study, 63 
the sensitivity and specificity of FNAC in the detection of LN neoplasia were 66.6% and 64 
91.5%, respectively.10 However, the latter study was primarily designed to determine the 65 
agreement between FNAC and histopathology for diagnosing nodal neoplasia, and was not 66 
specifically designed to assess the accuracy of FNAC in the setting of solid tumor staging.10  67 
In human oncology practice, LN extirpation followed by histopathologic examination 68 
is often performed to achieve an accurate clinical stage. An advantage of histopathologic 69 
  
examination is the possibility of obtaining multiple tissue sections, and to allow the use of a 70 
comprehensive immunohistochemistry panel and/or other further assessments (e.g. PCR-71 
based assessments), which might be necessary to improve the accuracy of staging.11 72 
However, depending on the location and number of LNs removed, LN extirpation can be 73 
associated with complications and can have a negative impact on the quality of life of cancer 74 
patients.12, 13 The value of sentinel LN extirpation for the staging of several tumor types is 75 
currently under investigation. Many studies report an increase in the appropriateness of each 76 
LN extirpation using this approach, while decreasing the morbidity associated with routine, 77 
unguided and extensive LN dissection.12, 14 Some studies have investigated the possible utility 78 
of FNAC in the staging of human breast, head, and neck cancer, but the sensitivity of FNAC 79 
to detect metastasis was generally poor.15-17 However, other studies have suggested a role for 80 
ultrasound-guided FNAC of sentinel LNs, in the staging of other tumor types, in particular 81 
when used in a step-wise approach.18-21 82 
Only two relatively small prospective studies have assessed the accuracy of FNAC for 83 
LN staging in dogs, both finding good agreement with histopathology.8, 9  A more recent, 84 
large retrospective study found that FNAC was poorly sensitive in detecting LN neoplasia, 85 
however this study was not specifically designed to assess this technique in the setting of 86 
routine LN staging.10 We sought to enhance the evidence base in this area by designing a 87 
study to assess the reliability of FNAC for LN staging in dogs presented with a solid tumor. 88 
We also sought to elucidate the impact of non-diagnostic FNAC in the routine staging of 89 
canine solid tumors, as this limitation of FNAC had not been assessed before. Similarly, as 90 
previous studies assessed only one LN per tumor, 8, 10 acknowledging that tumors can 91 
metastasize to several LNs, sometimes ”skipping” the anticipated local LN, 22-24 our study 92 
included the assessment of several LNs and the impact of such wider LN sampling on staging 93 
results.  The primary objectives of this study were two-fold: 1) to evaluate the reliability of 94 
  
FNAC compared with histopathology in the staging of canine malignant solid tumors, and 2) 95 
to evaluate the clinical significance of non-diagnostic FNAC in the staging of canine 96 
malignant solid tumors. A secondary objective was to determine the impact of multiple LN 97 
assessment in the staging of canine malignant solid tumors. 98 
Materials and methods 99 
Data collection 100 
Medical records of dogs presented to the University of Edinburgh Veterinary 101 
Teaching Hospital between February 2012 and February 2017 were reviewed to identify dogs 102 
with a histopathologic diagnosis of a malignant solid tumor with regional LN sampling. In all 103 
cases of histiocytic sarcomas and cutaneous lymphomas included in the study, no sign of 104 
distant involvement was noted at initial staging; which included thoracic radiographs, 105 
abdominal ultrasound, FNAC of liver and spleen, and bone marrow aspirate. Cases were 106 
included in this retrospective study if both FNAC and histopathology of LN(s) were 107 
available, and if the interval between FNAC and LN extirpation was <30 days.  In some 108 
cases, several locoregional LNs were assessed by both methods in staging a single tumor. 109 
May-Grünwald-Giemsa-stained FNAC preparations were assessed by board-certified clinical 110 
pathologists, while histopathologic sections were routinely stained with H&E and assessed by 111 
board-certified anatomic pathologists.  112 
Information collected from the medical records included dog signalment, tumor 113 
characteristics (histopathologic diagnosis, anatomic location and lateralization), LN 114 
characteristics (anatomic location, size, enlargement status (enlarged/not enlarged), use of 115 
ultrasound-guidance for FNAC, date of FNAC, date of extirpation). Tumor types were 116 
grouped into: sarcomas, carcinomas, melanomas, mast cell tumors, or other round cell 117 
tumors. Lymph node location was classified as: mandibular, prescapular, inguinal, popliteal, 118 
  
sublumbar, or others. Determination of LN enlargement status was based on clinical 119 
examination and was classified as: none, mild, moderate, or marked. Although subjective, 120 
enlargement status was preferred to measured size for statistical analysis, as validated 121 
information defining the normal size of a normal LN for specific breeds and locations is still 122 
lacking, and as such categorization accurately reflects clinical practice. When the cellularity 123 
of the sample was too low to allow cytological LN assessment, FNAC was considered non-124 
diagnostic. The LN metastatic status for both cytologic and histopathologic examinations was 125 
categorized as positive or negative. When metastasis was only suspected, a positive 126 
metastatic status was attributed to the LN. Cytologic and histopathologic criteria for the 127 
diagnosis of nodal mast cell tumor metastasis have previously been proposed.25, 26 These 128 
criteria were not systematically used in the original reports, but were retrospectively applied 129 
whenever possible. 130 
Reliability of LN FNAC 131 
Only LNs with diagnostic FNAC were selected for this analysis. The sensitivity and 132 
specificity of FNAC in the detection of nodal metastasis was determined for all LNs and 133 
subsequently for each tumor group, using histopathologic examination as the gold standard. 134 
The possible influence of factors such as LN enlargement, time between FNAC and LN 135 
extirpation, and LN location, on the failure to obtain agreement between FNAC and 136 
histopathology was evaluated. Cases with false-negative and false-positive FNAC reports were 137 
reviewed in an attempt to find an explanation for the discrepancy with histopathology. 138 
Significance of non-diagnostic LN FNAC 139 
The proportion of non-diagnostic FNAC was determined overall and for each tumor 140 
group. The possible influence of several factors on the failure to obtain a diagnostic FNAC, 141 
such as LN enlargement status, ultrasound-guidance, and LN location, was evaluated. The 142 
  
prevalence of histopathologic metastasis among the LNs with non-diagnostic FNAC was 143 
determined and compared to that among the LNs with diagnostic FNAC. 144 
Significance of multiple nodal metastases 145 
Tumors included in the study were reviewed and separated in two groups: tumors which 146 
had several LNs aspirated and removed for staging, and tumors which had a single LN assessed. 147 
The proportion of each LN location, the prevalence of metastasis, and LN enlargement status 148 
were compared between the two groups. Among the tumors with multiple LNs assessed 149 
histopathologically, the prevalence of metastasis to several LNs was determined. The patterns 150 
of metastasis to several LNs was reviewed. 151 
Statistical analysis 152 
 Differences in the prevalence of metastasis between the four subgroups of enlargement status 153 
(none, mild, moderate, marked) were assessed using Fisher’s exact test on pairwise 154 
comparisons and applying the Bonferroni correction.  Differences in the prevalence of 155 
metastasis between the non-diagnostic and diagnostic FNAC subgroups, the tumors with 156 
multiple LNs and tumors with single LN assessed; the difference in overall agreement and 157 
agreement within each LN location; the difference in proportion of ultrasound guidance 158 
between the non-diagnostic and diagnostic FNAC subgroups; and the difference in proportion 159 
of specific LN locations sampled between the tumors with multiple LNs assessed and those 160 
with a single LN assessed were analyzed using the chi-square test of homogeneity and 161 
Fisher’s exact test where appropriate.  Mann-Whitney U test was used to assess differences in 162 
LN enlargement status between the metastatic and non-metastatic LN subgroups; the non-163 
diagnostic and diagnostic FNAC subgroups; the tumors with multiple LNs sampled and those 164 
with a single LN sampled; and the correlation of the interval between FNAC and LN 165 
extirpation and FNAC-histopathology agreement. The 95 % confidence intervals (CI) were 166 
  
calculated using the exact binomial method. Statistical analyses were performed using 167 
commercially available statistics software (Minitab™ 17 Statistical Software; Minitab Inc., 168 
State College, Pennsylvania, PA, USA). A P-value of < 0.05 was considered statistically 169 
significant for all analyses.  170 
Results 171 
Three hundred and thirty-seven LNs investigated because of neoplasia were initially 172 
recruited to the study. Seventy-eight of these cases were excluded, 75 because FNAC had not 173 
been attempted prior to LN extirpation, and 3 because the time between FNAC and 174 
histopathology was > 30 days. The 259 remaining LNs included in this study were assessed 175 
for the staging of 189 tumors in 187 dogs. Primary tumors included a variety of different 176 
types, grouped as sarcomas (47 LNs assessed), carcinomas (46 LNs), melanomas (37 LNs), 177 
mast cell tumors (110 LNs), and other round cell tumors (19 LNs) (Table 1). One hundred 178 
and ninety-four of the FNACs were diagnostic in quality, while the remaining 65 FNACs 179 
were non-diagnostic.  180 
The median time between FNAC and LN extirpation was 7 days (1 – 30 days). 181 
Ultrasound guidance was used in 16.5% (n=32) of the FNACs. The overall prevalence of 182 
metastasis, based on histopathologic examination, was 32.4 % (n=84). The anatomic site of 183 
the LNs were mandibular (n = 132), prescapular (n = 51), popliteal (n = 34), inguinal (n = 184 
18), sublumbar (n = 17) and others (n = 7). 185 
Lymph nodes were deemed not enlarged in 58.3% (n=151) of cases, mildly enlarged 186 
in 19.7% (n=51) of cases, moderately enlarged in 14.7% (n=38) of cases, and markedly 187 
enlarged in 7.3% (n=19) of cases. There was a significant difference in the prevalence of 188 
metastasis when the LNs were stratified by enlargement status (P = 0.006) (Figure 1). Nodes 189 
with metastatic disease were significantly more likely to be deemed enlarged than non-190 
  
metastatic LNs in dogs bearing sarcomas (P = 0.048), carcinomas (P < 0.001), melanomas (P 191 
= 0.035), and mast cell tumors (P < 0.001), although statistics did not yield significant 192 
difference in dogs bearing other round cell tumors (P = 0.351). All the markedly enlarged 193 
LNs were assessed for the staging of dogs bearing either apocrine gland anal sac 194 
adenocarcinomas or mast cell tumors. The normal nodal architecture was effaced and 195 
replaced by neoplastic cells in all the LNs deemed markedly enlarged, with the exception of 196 
only one non-metastatic LN which had moderately disorganized architecture but no 197 
neoplastic cells were observed.  198 
Reliability of LN FNAC 199 
Among the 194 LNs with diagnostic FNAC, 35 were from dogs bearing a sarcoma, 34 200 
were from dogs bearing a carcinoma, 30 were from dogs bearing a malignant melanoma, 78 201 
were from dogs bearing a mast cell tumor, and 17 were from dogs bearing another round cell 202 
tumor. Using histopathologic examination as the gold standard, the overall sensitivity of FNAC 203 
in the detection of LN metastasis was 81% (58/71; CI 70-89%), the overall specificity was 91% 204 
(112/123; CI 84 – 95%), and the overall agreement was 88% (170/194; CI 82-92%). The 205 
sensitivity and specificity of FNAC were also determined individually for the 5 previously 206 
defined tumor groups (Table 2). Grouping FNACs into those which agreed and those which 207 
disagreed with histopathology, there was no significant difference in the time between FNAC 208 
and LN extirpation (P = 0.751), nor in LN enlargement status (P = 0.587). When compared to 209 
the overall agreement between FNAC and histopathologic examination, there was no 210 
significant difference in agreement for each LN anatomic location. 211 
Among the 13 false-negative FNAC results recorded, 2 were from dogs bearing a 212 
sarcoma, 3 from dogs bearing a malignant melanoma, and 8 from dogs bearing a mast cell 213 
tumor. In one of the sarcoma-bearing dog with a false negative FNAC, the LN was removed 214 
  
15 days later and histopathologic examination revealed a completely effaced LN by neoplastic 215 
tumor cells. The dog was euthanized 3 weeks later due to progressive disease. In the second 216 
case, the LN was removed a couple of days after the FNAC, and a 400µm metastatic deposit 217 
was noted within the corticomedullary junction. The LN bed was treated with radiation therapy 218 
and the dog was still free of disease a year later. All 3 melanoma-bearing dogs with a false 219 
negative FNAC were euthanized within a few months of investigation with generalized 220 
metastatic disease. In all 3 of these cases, pigmented cells and some large non-pigmented cells 221 
were observed on FNAC and interpreted as melanophages or macrophages. In all 8 cases of 222 
false-negative FNACs from dogs bearing a mast cell tumor, only small numbers (<1%) of 223 
individualized, well-differentiated mast cells were noted on cytology. In most histopathologic 224 
examinations of these cases, marked increases in individualized mast cells or mast cell 225 
aggregates were noted, sometimes associated with atypical morphology, corresponding to the  226 
HN1 and HN2 classes of the histopathologic classification scheme for mast cell tumor LN 227 
metastasis previously proposed.25 In only one such LN did histopathologic examination reveal 228 
a focal effacement of the normal nodal architecture by mast cells (consistent with HN3 class).25 229 
Toluidine blue (TB) staining was performed in 3 LNs from dogs bearing a mast cell tumor, 230 
which confirmed pre-metastasis (HN1 class) in one case, early metastasis (HN2 class) in 231 
another, and refuted the diagnosis of possible metastasis based on prior H&E in the third case.25  232 
Among the 11 false-positive FNACs recorded, 4 were from dogs bearing a mast cell 233 
tumor, 2 from dogs bearing a malignant melanoma, 2 from dogs bearing a carcinoma, 2 from 234 
dogs bearing non-epitheliotropic cutaneous lymphoma, and 1 from a dog bearing a sarcoma 235 
(“high-low” maxillary fibrosarcoma). Interestingly, in the latter case, moderate number of 236 
mesenchymal cells with moderate anisocytosis and anisokaryosis were seen on FNAC and 237 
were interpreted as neoplastic; however, on histopathologic examination the mesenchymal 238 
cells observed, were interpreted as reactive cells related to the presence of multifocal fibrinoid 239 
  
necrosis of arteriolar walls and associated fibroplasia. At the time of writing, 3 years after the 240 
initial diagnosis, this dog continues to be regularly rechecked and remains free of disease, after 241 
incomplete excision and definitive-intent radiation therapy of the primary site. In the 2 cases 242 
of non-epitheliotropic cutaneous lymphoma with a false-positive LN FNAC, uncertainty 243 
regarding the cytologic metastatic diagnosis was mentioned by the clinical pathologist, 244 
however metastasis was strongly favored. One case had definitive-intent radiation therapy 245 
delivered to a solitary lesion on right carpus based on a lack of dissemination on initial 246 
histopathology of the draining LN, but developed disseminated disease 4 months later. The 247 
other case had a solitary lesion on the lip which was completely excised, but the dog was lost 248 
to follow-up. In the 2 cases of carcinoma with a false-positive FNAC report, cohesive clusters 249 
of cells with an appearance compatible with the primary carcinoma (thyroid carcinoma and 250 
apocrine gland anal sac adenocarcinoma) were noted on cytology, but similar cells were not 251 
observed on histopathology despite requesting additional sections and cytokeratin 252 
immunohistochemistry. Both of these dogs were lost to follow-up. In the 2 cases of melanoma 253 
with a false-positive FNAC report, uncertainty regarding the cytologic metastatic diagnosis 254 
was mentioned by the clinical pathologist. Melanophages and fewer scattered melanocytes 255 
were described on both FNAC and histopathology, but in the latter were interpreted as a 256 
drainage reaction rather than metastasis as no cellular aggregates or atypia were present. Both 257 
of these dogs were lost to follow-up. In all 4 cases of mast cell tumor with a false-positive 258 
FNAC, uncertainty regarding the cytologic metastatic diagnosis was expressed by the clinical 259 
pathologist; increased number of individualized mast cells (up to 10 per high-power field), 260 
aggregates of 2-3 cells or loose groups of up to 8 cells, and moderate anisocytosis were noted 261 
on cytology. Unfortunately, the previously proposed cytologic criteria were not applied in the 262 
original FNAC reports and could not be retrospectively applied using the detail therein.26 263 
Although the features noted on FNAC were also described on histopathology, they were 264 
  
considered not to be consistent with metastasis. Unfortunately, the previously proposed 265 
histopathologic criteria were not applied in the original reports and could not be retrospectively 266 
applied using the detail therein;25 but no disruption or effacement of normal nodal architecture 267 
was reported. Toluidine Blue staining was performed in one case, and was supportive of the 268 
non-metastatic diagnosis made on routine histopathology. Two of these dogs were lost to 269 
follow-up after 5 and 7 months, and the other two dogs were free of disease at the time of 270 
writing, 1 and 2 years after diagnosis, following complete excision in one case, and incomplete 271 
excision with adjuvant definitive-intent radiation therapy on the primary site in the second case. 272 
Significance of non-diagnostic LN FNAC 273 
Twenty-five percent of the FNACs were non-diagnostic. Among the 65 LNs with non-274 
diagnostic quality FNAC, 12 were from dogs bearing a sarcoma, 12 a carcinoma, 7 a 275 
melanoma, 32 a mast cell tumor, and 2 another round cell tumor.  276 
Lymph nodes with  FNAC of non-diagnostic quality were significantly less likely to be 277 
deemed enlarged than were LNs with  FNAC of diagnostic quality (P < 0.001) (Figure 2). 278 
Overall, most of the LNs with FNAC samples of non-diagnostic quality were not (n=50) to 279 
mildly enlarged (n=13), with the exception of 2 moderately to markedly enlarged LNs which 280 
were sampled using ultrasound guidance. Fine-needle aspiration cytology samples of non-281 
diagnostic quality were significantly more frequently sampled with ultrasound guidance than 282 
were FNAC samples of diagnostic quality (P = 0.002) (Figure 3). When compared to the overall 283 
proportion of FNAC samples of non-diagnostic quality (65/259), the only anatomic site which 284 
had a significantly higher proportion of FNAC samples of non-diagnostic quality was the 285 
inguinal LN (P < 0.001). However, the majority of the inguinal LNs sampled were guided by 286 
ultrasound (16/18) and were deemed not enlarged (12/18). The prevalence of 287 
histopathologically-proven metastasis was 20.0% among the LNs with non-diagnostic FNAC, 288 
  
and 35.5% among the LNs with diagnostic FNAC, and this was significantly different (P = 289 
0.021) (Figure 4). 290 
Significance of multiple nodal metastases 291 
 Among the 189 dogs with a tumor included in the study, 88 cases had at least 2 LNs 292 
histopathologically assessed for staging as these LNs were thought to possibly drain the 293 
primary mass/be involved in the disease process. The tumors types with multiple LNs 294 
assessed included 14 sarcomas, 20 carcinomas, 18 melanomas, 29 mast cell tumors, and 7 295 
other round cell tumors. Eighty of these dogs had 2 LNs extirpated, 7 had 3 LNs extirpated, 296 
and 1 oral malignant melanoma-bearing dog had 4 LNs extirpated. Lymph nodes removed 297 
included those in the mandibular (132, including 64 bilateral and 4 unilateral extirpations), 298 
prescapular (13, including 3 bilateral and 7 unilateral extirpations), popliteal (2, unilateral 299 
extirpations), inguinal (11, including 5 bilateral and 1 unilateral extirpations), sublumbar (15, 300 
including 7 bilateral and 1 unilateral extirpations) and other regions (14). Compared to cases 301 
with solitary LNs assessed, among the cases with multiple LNs assessed, there was a lower 302 
proportion of popliteal and prescapular LNs, but a higher proportion of mandibular LNs (P < 303 
0.001). This is in part explained by the frequent bilateral extirpation of mandibular LNs in 304 
cases bearing tumors located on the head in the authors’ service. The overall prevalence of 305 
metastasis was 38.6% (34/88) among the cases with multiple LNs assessed, and 34.7 % 306 
(35/101) among the cases with only one LN assessed, which was not significantly different 307 
(P = 0.650). There was no significant difference in the enlargement status of the LNs whether 308 
cases had single or multiple LNs assessed (P = 0.762). Among the cases with multiple LNs 309 
assessed, the prevalence of having ≥2 metastatic LNs was 23.9% (21/88) while 14.8% 310 
(13/88) of tumors with multiple LNs assessed had evidence of metastasis in only one LN. 311 
Therefore, of those tumors with metastasis which had multiple LNs sampled, 61.8% (21/34) 312 
of cases had metastasis to multiple LNs. Tumors types metastasizing to multiple LNs were 313 
  
carcinomas (n=10), mast cell tumors (n=6), oral malignant melanomas (n=4), and one 314 
sarcoma (Table 3).  315 
Discussion 316 
 Lymph node enlargement status was significantly associated with tumor metastasis in 317 
our study. This was true for all the tumor groups included in our study with the exception of 318 
other round cell tumors, possibly because of a type II error. Nevertheless, the prevalence of 319 
metastasis among non-enlarged LNs was also substantial (15%). This finding is consistent 320 
with one of the two previous studies conducted specifically on malignant melanomas, in 321 
which the prevalence of metastasis among non-enlarged LNs was also 15%,21 but the rate 322 
was  40% in the other study.27  323 
The overall specificity of FNAC for the detection of tumor metastasis found in our 324 
study (91%) was similar to that found in a previous study (91.5%), however, the overall 325 
sensitivity was superior in our study (81%) compared to the same previous study (66.6%).11 326 
This could be explained by differentiating features of this previous study in which cytologic 327 
and histopathologic examinations were not always performed on the same LN, the time 328 
interval between cytologic and histopathologic examinations was up to 80 days, and cases of 329 
multicentric lymphoma were included.10 Nonetheless, our results concur that although of high 330 
value and practicality, LN histopathologic examination cannot always be reliably substituted 331 
with FNAC.  332 
The relatively low sensitivity of FNAC for detecting metastatic sarcomas in LNs 333 
(67%), also reported in a previous study,10 could be related, at least in part, to the poorly 334 
exfoliative nature of sarcomas limiting the representativeness of FNAC.28 The relatively poor 335 
sensitivity of FNAC for detecting metastatic malignant melanomas in LNs (63%), has also 336 
been anecdotally reported before.27, 29 In one study assessing the efficacy of systemic 337 
  
adjuvant therapies in dogs with excised oral malignant melanoma, 41 dogs had both cytologic 338 
and histopathologic examinations of at least one LN, and the sensitivity and specificity of 339 
FNAC were 78.1% and 64.1% , respectively.29 The specificity found in our study was 340 
superior (91%), but these results highlight the difficulty in differentiating melanophages from 341 
melanocytes, which is a challenge for both cytologic and histopathologic examinations. The 342 
American Joint Committee on Cancer (AJCC) published guidelines for the use of 343 
immunohistochemistry in the evaluation of melanoma-draining sentinel LNs in human 344 
oncology practice, to facilitate the distinction between melanocytes and histiocytes.11  The 345 
identification of even single-cell metastasis in a sentinel LN is now considered sufficient to 346 
categorize patients as having dissemination.11, 30 With the increasing use of sensitive 347 
techniques for the detection of melanoma metastasis (immunohistochemistry, PCR), the 348 
challenge to accurately differentiate malignant from benign melanocytes has become even 349 
more important. 31, 32 Although these challenges have not been as clearly researched in canine 350 
oncology practice, routine histopathologic examination alone is likely to be a suboptimal gold 351 
standard for canine melanoma nodal metastasis assessment. This has been highlighted in a 352 
recent study, in which the diagnosis of LN melanoma metastasis was changed in 46.9% of 353 
dogs upon second opinion histopathology review.33 This might also explain in part why 354 
several studies failed to find a prognostic value of LN metastasis in dogs,29, 34, 35 while LN 355 
metastatic status is of important prognostic value in human melanoma.36 The robustness of 356 
assessment of the diagnostic utility of FNAC for the detection of melanoma nodal metastasis 357 
would be enhanced by an optimal gold standard, based on the results of a future comparison 358 
of histopathology, immunohistochemistry, PCR, and combinations thereof, incorporating 359 
follow-up. 360 
Although one study found a perfect agreement between cytologic and histopathologic 361 
examination for the detection of mast cell tumor nodal metastasis,37 the relatively low 362 
  
sensitivity (75%) found in our study is more consistent with that reported in another study 363 
(68.7%).10 Cytologically it is often very difficult to differentiate reactive from well 364 
differentiated neoplastic mast cells within LN aspirates. Clinical pathologists often rely on 365 
the presence of the overall numbers of mast cells, their aggregation, and/or morphologic 366 
abnormalities to make such a distinction. It is therefore often difficult to determine the 367 
metastatic status of LNs draining canine mast cell tumors either cytologically or 368 
histopathologically. Criteria have previously been proposed to standardize the definition of 369 
mast cell tumor nodal metastasis for both techniques.25, 26 These criteria were not 370 
systematically applied in our study, which makes it difficult to comment meaningfully on the 371 
sensitivity and specificity obtained by using the proposed criteria. A prospective study with 372 
the systematic application of these criteria for cytologic and histopathologic examination, 373 
together with follow up, would be necessary for a more reliable evaluation of FNAC 374 
accuracy.  It should also be underlined that in all 4 false-positive FNACs assessing mast cell 375 
tumor LN metastases, the clinical pathologist expressed some uncertainty regarding the 376 
metastatic status; and for only 1/8 false-negative such FNACs, was the corresponding 377 
histopathologic classification HN3 (overt metastasis).25 Furthermore, TB staining invalidated 378 
the diagnosis of LN metastasis made initially on routine histopathology in 1 case, and the 379 
systematic use of TB staining might alter the determined sensitivity and specificity of FNAC 380 
in the detection of mast cell tumor nodal metastasis.  381 
Non-diagnostic FNAC was reported in 25% of our cases. This is comparable to the 382 
results of another study (27.2%) although only 9.3% of the LNs sampled were for tumor 383 
staging purposes in that study.7 In another study, only 5.7% of the cytologic samples were 384 
deemed non-diagnostic,10 but again the study did not exclusively include LNs FNAC sampled 385 
for tumor staging as in the current study. The results of our study suggest that FNAC might 386 
be technically limited for non-enlarged and/or deep LNs for which a diagnostic-quality 387 
  
sample might not be easily obtainable. Size of the LN is a recognized limiting factor of 388 
FNAC in human medicine, and it is often observed that LN < 5 mm are difficult to sample.16 389 
Histopathologic assessment of local LNs when FNAC is not possible because of a LN’s 390 
inaccessible location or small size has been recommended by some authors.22 Our results 391 
support this recommendation, as when diagnostic samples could not be obtained by FNAC in 392 
such LNs, the prevalence of metastasis remained substantial on histopathology (20%). 393 
In previous studies, LN examination for tumor staging was limited to a single LN.5, 8, 394 
10, 26, 37 In our study, 46.5% of the tumors had several LNs assessed for staging. The 395 
prevalence of metastasis within several LNs was 23.9%, suggesting that staging should not 396 
always be limited to the assessment of a single LN. This is in agreement with the results 397 
obtained with routine extirpation of bilateral mandibular and medial retropharyngeal 398 
lymphadenectomy for  staging of head-based tumours,38 and with the use of sentinel LNs.22, 399 
23, 39, 40 It remains for further research to investigate whether such cases have a worse 400 
prognosis when compared to those cases with a solitary LN metastasis. However, such results 401 
are very likely significant from a therapeutic aspect, if the response to an additionally 402 
metastatic LN were to be the use of a local therapy modality (i.e. surgical extirpation and/or 403 
irradiation) rather than systemic therapy modalities that might already be triggered by even a 404 
solitary metastatic LN. In our study, most of the tumors that were investigated for several 405 
metastatic LNs were located in the head and involved mandibular LNs, or were anal sac 406 
adenocarcinomas involving sublumbar LNs, which is consistent with other studies.6, 38 407 
Notably, we report the occurrence of bilateral prescapular LN involvement in 3 tumors (2 408 
mast cell tumors on the midline neck and 1 thyroid carcinoma), and bilateral inguinal LN 409 
involvement in 1 scrotal mast cell tumor.  As systematic bilateral assessment of local LNs 410 
have been recommended for head-based tumors,38 bilateral nodal assessment for other 411 
locations could be of value, although this requires further investigation.  412 
  
This study had several limitations, most of them being the consequence of its 413 
retrospective design. Cytologic and histopathologic examination was performed by different 414 
pathologists all of whom were board certified, although the sections were not systematically 415 
reviewed for the purposes of the study, therefore contributing to an inter-observer variation. 416 
In particular, previously proposed cytologic and histopathologic criteria for the diagnosis of 417 
mast cell tumor metastasis were not systematically applied.25, 26 Cytological findings in some 418 
cases do not allow a certain diagnosis to be reached but they can point to a suspicion that 419 
needs to be confirmed through other methods. However, for the purpose of the study, 420 
metastatic status was dichotomized into “metastatic” and “non-metastatic”. Because dogs 421 
were assessed by different clinicians, the recording of LN enlargement status was subject to 422 
inter-observer variation. However, we believe that this effect was minimal as a significant 423 
difference in the prevalence of metastasis was noted for each tumor subgroup, and this 424 
approach reflects clinical practice. There was a variable interval between cytologic and 425 
histopathologic assessments, which could have affected their agreement, although this was 426 
intentionally limited. However, there was no significant difference in the interval between 427 
FNAC and histopathologic assessments between the LNs with agreement and those with 428 
disagreement.  429 
Conclusions 430 
 In our study FNAC appeared to be a reliable tool to detect metastatic carcinomas and 431 
round cell tumors in LNs. Conversely, the sensitivity of FNAC in the detection of nodal 432 
metastasis was relatively low for sarcomas, melanomas and mast cell tumors. Although 433 
FNAC remains a non-invasive and affordable test typically obviating general anesthesia, 434 
when a negative result is obtained in these tumors, additional histopathologic assessment 435 
should be recommended for more robust staging information. Non-diagnostic FNAC reports 436 
are frequently encountered (25%) when staging tumor-draining LNs, particularly when the 437 
  
LNs sampled are non-enlarged and/or have a deep location. Further histopathologic 438 
examination should be recommended in these cases, as the risk of metastasis in the non-439 
diagnostic LN aspirates was 20% in our study. Finally, metastasis to multiple LNs seems to 440 
be relatively frequent, making investigation of multiple LNs valuable diagnostically and 441 
therapeutically.  442 
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Tables 552 
Table 1. Primary tumor types with corresponding number of LNs. 553 
Tumor type Number of LNs 
Sarcomas 47 
Osteosarcoma 17 
Soft Tissue Sarcoma 10 
Sarcoma (not specified) 10 
Fibrosarcoma  7 
Hemangiosarcoma 2 
Chondrosarcoma 1 
Carcinomas 46 
Apocrine gland anal sac adenocarcinoma 16 
Oral squamous cell carcinoma 11 
Thyroid carcinoma 8 
Salivary gland adenocarcinoma 3 
Gingival basosquamous cell carcinoma 2 
Sebocytic sebaceous carcinoma 2 
Mammary carcinoma 1 
Pulmonary carcinoma 1 
Cutaneous carcinoma (not specified) 1 
Hepatocellular carcinoma 1 
Malignant melanomas 37 
Oral 32 
Cutaneous 5 
  
Mast cell tumors 110 
Cutaneous 77 
Subcutaneous 20 
Mucosal 9 
Muco-cutaneous 4 
Other round cell tumors 19 
Oral plasma cell tumor 10 
Histiocytic sarcoma 6 
Non-epitheliotropic T-cell lymphoma 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2. Sensitivity, specificity, positive and negative predictive values (and 95% 554 
confidence intervals) of LN FNAC in the detection of tumor metastasis. 555 
Tumor types 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Sarcomas 67% (24-94%) 96% (80-99%) 80% (30-99%) 93% (76-99%) 
Carcinomas 100% (82-100%) 83% (51-97%) 92% (72-99%) 100% (66-100%) 
Malignant melanomas 63% (26-89%) 91% (69-98%) 71% (30-95%) 87% (65-97%) 
Mast cell tumors 75% (57-88%) 91% (77-97%) 86% (76-95%) 84% (70-92%) 
Other round cell tumors 100% (20-100%) 87% (58-97%) 50 (10-91%) 100% (72-100%) 
 
PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval 556 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3. Data regarding the tumors with several metastatic LNs. 557 
Case  
Number 
Primary tumor   Lymph nodes 
Tumor type Location Lateralization   Location Lateralization Enlargement Metastasis 
1 
Apocrine gland anal sac 
adenocarcinoma 
Anal sac R  
Medial iliac R 3 Y 
 
Medial iliac L 0 Y 
2 
Apocrine gland anal sac 
adenocarcinoma 
Anal sac R 
  Medial iliac R 3 Y 
 
Medial iliac L 3 Y 
3 
Apocrine gland anal sac 
adenocarcinoma 
Anal sac L 
  Medial iliac L 3 Y 
 
Medial iliac R 2 N 
 
Sacral L 2 Y 
4 
Apocrine gland anal sac 
adenocarcinoma 
Anal sac R 
  Medial iliac R 3 Y 
 
Medial iliac L 3 Y 
5 
Apocrine gland anal sac 
adenocarcinoma 
Anal sac L 
  Medial iliac L 3 Y 
 
Hypogastric L 3 Y 
6 
Apocrine gland anal sac 
adenocarcinoma 
Anal sac R 
  Medial iliac R 3 Y 
 
Medial iliac L 3 Y 
7 
Thyroid carcinoma 
Thyroid 
gland 
R 
  Mandibular R 2 Y 
 
Mandibular L 2 Y 
 
Prescapular R 2 Y 
8 
Thyroid carcinoma 
Thyroid 
gland 
L 
  
Medial 
retropharyngeal 
L 1 Y 
 
Prescapular L 2 Y 
 
Prescapular R 1 Y 
9 
Squamous cell carcinoma Tonsil L 
  Mandibular L 2 Y 
 
Mandibular R 0 Y 
 
Medial 
retropharyngeal 
L 3 Y 
10 
Salivary gland 
adenocarcinoma 
Parotid  
salivary 
gland 
R 
  Parotid R 0 Y 
 
Medial 
retropharyngeal 
R 1 Y 
 
Mandibular R 0 N 
11 
Malignant melanoma Maxilla L 
  Mandibular L 2 Y 
 
Mandibular R 0 Y 
12 
Malignant melanoma Maxilla R 
  Mandibular R 1 Y 
 
Mandibular L 1 Y 
13 
Malignant melanoma Maxilla L 
  Mandibular L 2 Y 
 
Mandibular R 0 Y 
14 
Malignant melanoma Mandible R 
  Mandibular R 0 Y 
 
Mandibular L 0 Y 
15 
Mast cell tumor (mucosal) Upper lip L 
  Mandibular L 2 Y 
 
Mandibular R 0 Y 
16 
Mast cell tumor (cutaneous) 
Lower 
eyelid 
L 
  Mandibular L 3 Y 
 
Mandibular R 3 Y 
17 
Mast cell tumor (cutaneous) Scrotum M 
  Inguinal L 0 Y 
 
Inguinal R 0 Y 
18 Mast cell tumor (cutaneous) Carpus L   Prescapular L 3 Y 
  
 
Axillary L 3 Y 
19 
Mast cell tumor (cutaneous) 
Ventral 
neck 
M 
  Prescapular L 1 Y 
 
Prescapular R 0 Y 
20 
Mast cell tumor (cutaneous) Chest M 
  Prescapular L 2 Y 
 
Prescapular R 2 Y 
21 
Nasal sarcoma 
Nasal 
cavity 
R 
  Mandibular R 2 Y 
 
Mandibular L 2 Y 
 
Lateralization was classified as left (L), right (R) or midline (M). Enlargement was classified 558 
as none (0), mild (1), moderate (2), or marked (3). 559 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure captions 560 
Figure 1. Prevalence of metastasis stratified by LN enlargement. 561 
The error bars represent 95% confidence intervals. 562 
Figure 2. Lymph node enlargement among non-diagnostic and diagnostic cytology 563 
samples. 564 
The error bars represent 95% confidence intervals. 565 
Figure 3. Proportion of FNAC performed via ultrasound-guidance among non-566 
diagnostic and diagnostic FNAC samples. 567 
The error bars represent 95% confidence intervals. 568 
Figure 4. Prevalence of metastasis among the LNs with non-diagnostic and diagnostic 569 
FNAC samples. 570 
The error bars represent 95% confidence intervals. 571 
